Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 133Squamous Cell Carcinoma of Head and Neck 76Lung Neoplasms 49Head and Neck Neoplasms 45Urinary Bladder Neoplasms 43Parkinson Disease 4, Autosomal Dominant Lewy Body 33Oropharyngeal Neoplasms 32Nasopharyngeal Carcinoma 32Biliary Tract Neoplasms 31Uterine Cervical Neoplasms 30Cholangiocarcinoma 28Esophageal Squamous Cell Carcinoma 26Carcinoma 24Neoplasms 23Ovarian Neoplasms 22Neoplasm Metastasis 22Small Cell Lung Carcinoma 21Carcinoma, Squamous Cell 20Stomach Neoplasms 18Colorectal Neoplasms 18Carcinoma, Transitional Cell 17Pancreatic Neoplasms 16Esophageal Neoplasms 16Mesothelioma, Malignant 15Gallbladder Neoplasms 15Mouth Neoplasms 14Laryngeal Neoplasms 13Hypopharyngeal Neoplasms 12Endometrial Neoplasms 11Triple Negative Breast Neoplasms 10

Interventions

Valganciclovir 3Rituximab 3Cisplatin 3Vincristine 2Radiotherapy, Intensity-Modulated 2Prednisone 2Matrix-M 2Gemcitabine 2Etoposide 2Doxorubicin 2Cyclophosphamide 2pomalidomide 1dehydroftorafur 1brincidofovir 1Watchful Waiting 1Valacyclovir 1Tomography, X-Ray Computed 1Tenofovir 1Tegafur 1Taxes 1Platinum 1Phantoms, Imaging 1Paclitaxel 1Nivolumab 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitomycin 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferons 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × Cisplatin × 1 year × Clear all
NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Not yet recruiting
10 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT02363400 2025-08-19

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

National Health Research Institutes, Taiwan

Phase 3 Terminated
10 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡